The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.

[1]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[2]  P. Tchou,et al.  Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. , 2004, Journal of the American College of Cardiology.

[3]  Margaret T May,et al.  Statistical Methods for the Analysis of Repeated Measurements.Charles S Davis. Heidelberg: Springer Verlag, 2002, pp. 415, £59.50 (HB) ISBN: 0-387-95370-1. , 2003 .

[4]  James R. Kenyon,et al.  Statistical Methods for the Analysis of Repeated Measurements , 2003, Technometrics.

[5]  S. Nattel,et al.  New insights into the mechanisms and management of atrial fibrillation. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[6]  S. Connolly,et al.  Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. , 2001, The American journal of cardiology.

[7]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[8]  S. Borzak,et al.  Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. , 2001, Progress in cardiovascular diseases.

[9]  L. Køber,et al.  Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy , 2001, Circulation.

[10]  Kenneth Egstrup,et al.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.

[11]  S. Connolly,et al.  Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. , 2000, Journal of the American College of Cardiology.

[12]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[13]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[14]  Lauer.  Pharmacologic Conversion of Atrial Fibrillation. , 1998 .

[15]  A. Camm,et al.  The azimilide post-infarct survival evaluation (ALIVE) trial. , 1998, The American journal of cardiology.

[16]  V. Fuster,et al.  Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. , 1996, Circulation.

[17]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[18]  D. Collett.  Modelling Survival Data in Medical Research , 1994 .

[19]  D. Levy,et al.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.

[20]  S. Vaziri,et al.  Echocardiographic Predictors of Nonrheumatic Atrial Fibrillation: The Framingham Heart Study , 1994, Circulation.

[21]  G. Naccarelli,et al.  Amiodarone: clinical trials. , 2000, Current opinion in cardiology.